Linezolid Kabi

Linezolid

Nosocomial pneumonia caused by Staph aureus (methicillin-susceptible & -resistant isolates) or Strep pneumoniae. Community-acquired pneumonia caused by Strep pneumoniae including cases w/ concurrent bacteremia, or Staph aureus (methicillin-susceptible isolates only). Complicated skin & skin structure infections, including diabetic foot infections, w/o concomitant osteomyelitis, caused by Staph aureus (methicillin-susceptible & -resistant isolates), Strep pyogenes or Strep agalactiae. Vancomycin-resistant Enterococcus faecium, including cases w/ concurrent bacteremia.

IV infusion Administer over a period of 30-120 min. Nosocomial & community-acquired pneumonia, & complicated skin & skin structure infections Adult & adolescent ≥12 yr 600 mg every 12 hr for 10-14 days. Ped patient ≤11 yr 10 mg/kg every 8 hr for 10-14 days. Neonate <7 days 10 mg/kg every 12 hr. Vancomycin-resistant Enterococcus faecium infections Adult & adolescent ≥12 yr 600 mg every 12 hr for 14-28 days. Ped patient ≤11 yr 10 mg/kg every 8 hr for 14-28 days. Neonate <7 days 10 mg/kg every 12 hr.

Hypersensitivity. Patients taking MAOIs A or B (eg, phenelzine, isocarboxazid, selegiline, moclobemide) or w/in 2 wk of taking any such medicinal product; SSRIs, SNRIs, TCAs, MAOIs & other psychiatric medications.

Not for gm -ve infections. Consider Clostridium difficile-associated diarrhea in all patients who present w/ diarrhea following antibacterial drug use; careful medical history is necessary. Consider discontinuation in patients who develop or have worsening myelosuppression; monitor CBC wkly, particularly those treated for >2 wk, w/ pre-existing myelosuppression, receiving concomitant drugs that produce bone marrow suppression, or w/ chronic infection who received previous or concomitant antibacterial drug therapy. Caution for potential hypoglycemic reactions in diabetic patients. Reports of peripheral & optic neuropathy, primarily those treated for >28 days; serotonin syndrome associated w/ co-administration w/ serotonergic agents, including antidepressants eg, SSRIs; lactic acidosis; convulsions. Not to be administered to patients w/ carcinoid syndrome; uncontrolled HTN, pheochromocytoma, thyrotoxicosis &/or patients taking any of the following types of medications: directly & indirectly acting sympathomimetic agents (eg, pseudoephedrine), vasopressive agents (eg, epinephrine, norepinephrine), dopaminergic agents (eg, dopamine, dobutamine). Not for the treatment of catheter-related bloodstream infections or catheter-site infections. Has not been studied in the treatment of decubitus ulcers. Safety & efficacy of treatment for >28 days have not been evaluated. Additives should not be introduced into the soln. Administer separately when given concomitantly w/ another drug. Advise lactating women to monitor breastfed infant for diarrhea & vomiting. Not recommended for empiric treatment in ped patient w/ CNS infection.

Headache, diarrhea, nausea, vomiting, anemia, localized/generalized abdominal pain. Adults: Dizziness, rash, taste alteration, vag/oral moniliasis, abnormal LFTs, fungal infection, tongue discoloration. Ped patients: Thrombocytopenia, loose stools, eosinophilia, pruritus at non-application site, vertigo.

Potential interaction w/ adrenergic & serotonergic agents.

Other Antibiotics

J01XX08 - linezolid ; Belongs to the class of other antibacterials. Used in the systemic treatment of infections.

P₁S₁S₃